YERVOY® (ipilimumab)

Patient Alert Card

Date of UK Health Authority Approval: September 2022
Local Approval Number: 731-GB-2200009
Date of Preparation: September 2022

Bristol Myers Squibb™

Important Information for Patients

Carry this card with you at all times to inform healthcare professionals that you are receiving treatment with ipilimumab alone.

If you have any signs or symptoms, tell your doctor right away.

POSSIBLE SIDE EFFECTS	
BOWEL AND STOMACH	• diarrhoea (watery, loose or soft stools), bloody or dark-coloured stools • more frequent bowel movements than usual • pain or tenderness in your stomach or abdomen area, nausea, vomiting
LIVER	• eye or skin yellowing (jaundice) • pain on the right side of your stomach area • dark urine
SKIN	• skin rash with or without itching, dry skin • blisters and/or peeling of the skin, mouth sores • swelling of the face or lymph glands
EYE	• redness in the eye • pain in the eye • vision problems or blurry vision
NERVES	• muscle weakness • numbness or tingling in legs, arms or face • dizziness, loss of consciousness or difficulty waking up
GENERAL	• fever, headache, tiredness • bleeding • behavioural changes (e.g. less sex drive, being irritable or forgetful) • dehydration, low blood pressure, shock

Reporting of side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Side effects should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com.
By reporting side effects you can help provide more information on the safety of this medicine.

⚠ IMPORTANT

- Tell your doctor of any previous medical conditions.
- Early treatment of side effects reduces the likelihood that ipilimumab treatment will need to be temporarily or permanently stopped.
- Signs and symptoms that may appear mild can quickly worsen if left untreated.
- DO NOT try to treat these symptoms yourself.
- Signs and symptoms may be delayed and may occur weeks to months after your last ipilimumab injection.

For more information, read the ipilimumab Package Leaflet at www.medicines.org.uk/emc (UK - Great Britain), www.emcmedicines.com/en-GB/northernireland/ (UK - Northern Ireland) or call Medical Information on 0800 731 1736 for more information.

My Doctor's Contact Information ***(who prescribed ipilimumab)***

Name of Doctor: .....

Office Phone: .....

After-Hours Phone: .....

My Contact Information

My Name and Phone: .....

Caregiver Name and Phone (in case of emergency): .....

.....

ⓘ IMPORTANT Information for Healthcare Professionals

- This patient is treated with **ipilimumab** monotherapy.
- Immune-related adverse reactions (irARs) may appear at any time during treatment or months after its discontinuation.
- Early diagnosis and appropriate management are essential to minimise life-threatening complications.
- Consultation with an oncologist or other medical specialist may be helpful for management of organ-specific irARs.
- Healthcare professionals should refer to the ipilimumab Summary of Product Characteristics (SmPC) at www.medicines.org.uk/emc (UK - Great Britain), www.emcmedicines.com/en-GB/northernireland/ (UK - Northern Ireland) or call Medical Information on 0800 731 1736 for more information.

⚠ **The healthcare professional treating this patient with ipilimumab** should complete the **'My Doctor's Contact Information'** section of this Patient Alert Card.

Date of UK Health Authority Approval: September 2022
Local Approval Number: 731-GB-2200009
Date of Preparation: September 2022